Ad hoc announcement pursuant to Art. 53 LR

Zug, Switzerland, July 25, 2024 – Galderma Group AG, the pure-play dermatology category leader, today announced its financial results for the first half of 2024.

• Galderma, the pure-play dermatology category leader with a 40+ year heritage in dermatology, will present one oral, six symposia and four hub sessions demonstrating its scientific expertise and ongoing commitment to advancing dermatology
• 18 scientific and clinical posters will unveil new data on skin disease awareness and scientific innovation in prurig

• Latest data from the phase III OLYMPIA 2 trial presented at the World Congress of Dermatology (WCD) showcase rapid onset of action of nemolizumab in adult patients with prurigo nodularis, with 19.7% of patients treated with nemolizumab monotherapy achieving an itch-free state as early as week 4 after only one dose of nemolizumab^[1]

• Galderma will present findings from the ARTIST post-marketing study showing that The Shayping Technique™ – a holistic treatment approach using three Restylane^® injectables – significantly enhances facial features and overall appearance, supporting its use to meet diverse patient needs¹
• Additional presentations will highlight the versat